Literature DB >> 19104004

Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.

Toshio Kushiro1, Kyoichi Mizuno, Noriaki Nakaya, Yasuo Ohashi, Naoko Tajima, Tamio Teramoto, Shinichiro Uchiyama, Haruo Nakamura.   

Abstract

Lipid-lowering therapy in individuals with high risk of cardiovascular disease reduces the incidence of coronary heart disease. However, few studies have assessed the benefits of cholesterol lowering for primary prevention of coronary heart disease in hypertensive patients with mild dyslipidemia or without conventional dyslipidemia. The large, randomized Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study showed a 33% reduction in coronary heart disease incidence with pravastatin as the primary prevention in Japanese patients. We conducted an exploratory analysis of the effect of diet plus pravastatin therapy on the primary prevention of cardiovascular events (coronary heart disease, coronary heart disease plus cerebral infarction, and cardiovascular disease) in the 3277 patients with hypertension during the 5-year follow-up. There were no significant differences in mean baseline total cholesterol, blood pressure levels, or variation in blood pressure during the 5-year period between the diet (n=1664) and diet plus pravastatin (n=1613) groups. In the diet plus pravastatin group, the relative risk of coronary heart disease plus cerebral infarction was reduced by 35% (hazard ratio: 0.65; CI: 0.46 to 0.93; P=0.02), cerebral infarction by 46% (hazard ratio: 0.54; CI: 0.29 to 0.98; P=0.04), and cardiovascular disease by 33% (hazard ratio: 0.67; CI: 0.49 to 0.91; P=0.01). In patients without a history of cardiovascular disease who have hypertension and mildly elevated cholesterol, pravastatin was effective in reducing the incidence of cardiovascular disease, particularly cerebral infarction. Hence, in patients with hypertension with mildly elevated cholesterol levels, treatment with a statin is advisable to reduce the burden of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19104004     DOI: 10.1161/HYPERTENSIONAHA.108.120584

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Blood pressure, low-density lipoprotein cholesterol, and incidences of coronary artery disease and ischemic stroke in Japanese: the Suita study.

Authors:  Rumi Tsukinoki; Tomonori Okamura; Makoto Watanabe; Yoshihiro Kokubo; Aya Higashiyama; Kunihiro Nishimura; Misa Takegami; Yoshitaka Murakami; Akira Okayama; Yoshihiro Miyamoto
Journal:  Am J Hypertens       Date:  2014-04-08       Impact factor: 2.689

Review 2.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

Review 3.  Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.

Authors:  Kwang Kon Koh; Seung Hwan Han; Pyung Chun Oh; Eak Kyun Shin; Michael J Quon
Journal:  Atherosclerosis       Date:  2009-09-12       Impact factor: 5.162

4.  Antihypertensive effects of statins: a meta-analysis of prospective controlled studies.

Authors:  Alexandros Briasoulis; Vikram Agarwal; Antonis Valachis; Franz H Messerli
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-03-07       Impact factor: 3.738

5.  Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS).

Authors:  Yoji Nagai; Tatsuo Kohriyama; Hideki Origasa; Kazuo Minematsu; Chiaki Yokota; Shinichiro Uchiyama; Setsuro Ibayashi; Yasuo Terayama; Makoto Takagi; Kazuo Kitagawa; Eiichi Nomura; Naohisa Hosomi; Toshiho Ohtsuki; Takemori Yamawaki; Yoshihiro Matsubara; Masakazu Nakamura; Yoshimitsu Yamasaki; Etsuro Mori; Masanori Fukushima; Shotai Kobayashi; Yukito Shinohara; Takenori Yamaguchi; Masayasu Matsumoto
Journal:  Int J Stroke       Date:  2013-09-09       Impact factor: 5.266

6.  Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study.

Authors:  Ikuo Saito; Kazuomi Kario; Toshio Kushiro; Satoshi Teramukai; Natsuko Zenimura; Katsutoshi Hiramatsu; Fumiaki Kobayashi; Kazuyuki Shimada
Journal:  Hypertens Res       Date:  2012-10-25       Impact factor: 3.872

7.  The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study.

Authors:  Naohisa Hosomi; Yoji Nagai; Tatsuo Kohriyama; Toshiho Ohtsuki; Shiro Aoki; Tomohisa Nezu; Hirofumi Maruyama; Norio Sunami; Chiaki Yokota; Kazuo Kitagawa; Yasuo Terayama; Makoto Takagi; Setsuro Ibayashi; Masakazu Nakamura; Hideki Origasa; Masanori Fukushima; Etsuro Mori; Kazuo Minematsu; Shinichiro Uchiyama; Yukito Shinohara; Takenori Yamaguchi; Masayasu Matsumoto
Journal:  EBioMedicine       Date:  2015-08-06       Impact factor: 8.143

Review 8.  Efficacy and Safety of a Traditional Chinese Herbal Formula Xuefu Zhuyu Decoction for Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Pengqian Wang; Xingjiang Xiong; Shengjie Li
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.